Major Depressive Disorder Clinical Trial
Official title:
Effects of Treatment on Decision-making in Major Depression
In this trial, fifty participants with current major depressive disorder who are not receiving an antidepressant medication and fifty healthy controls will complete questionnaires and computerized tasks to assess their decision-making styles. There will be three visits for depressed patients and two for healthy controls (the first and third visits). The first visit will involve interviews and questionnaires to assess the participant's level of depression, medical history and quality of life. Participants will then complete the decision-making tasks, and will earn between $5-40 based on their choices, in order to make the decisions on the computer tasks financially meaningful. At the completion of this visit, depressed patients will be prescribed an FDA-approved antidepressant, chosen in consultation with the treating psychiatrist. Patients will be responsible for paying for the prescription themselves. After two weeks on the medication, the patient will be seen for a follow-up visit to ensure tolerability of the medicine. After six weeks on the medicine, patients and healthy controls will return to repeat the questionnaires and the computer based decision-making tasks, and will again earn between $5-40 based on their performance.
During episodes of depression patients with major depressive disorder (MDD) may make
sub-optimal decisions based on exaggerated negative beliefs about themselves, the future, or
the world around them. These disruptions in decision-making contribute adversely to quality
of life, in both work and personal realms. Although effective treatments for depression are
available, very little work has explored the effects of treatment on how people make
decisions. The specific aspects of decision-making that differ between depressed and health
control individuals are unknown, and whether any changes in these decision-making features
occur as a result of improvement from depression, or whether medication treatment itself can
lead to changes in decision-making, even in the absence of clinical improvement.
In this trial, fifty participants with current major depressive disorder who are not
receiving an antidepressant medication and fifty healthy controls will complete
questionnaires and computerized tasks to assess their decision-making styles. There will be
three visits for depressed patients and two for healthy controls (the first and third
visits). The first visit will involve interviews and questionnaires to assess the
participant's level of depression, medical history and quality of life. Participants will
then complete the decision-making tasks, and will earn between $5-40 based on their choices,
in order to make the decisions on the computer tasks financially meaningful. At the
completion of this visit, depressed patients will be prescribed an FDA-approved
antidepressant, chosen in consultation with the treating psychiatrist. Patients will be
responsible for paying for the prescription themselves. After two weeks on the medication,
the patient will be seen for a follow-up visit to ensure tolerability of the medicine. After
six weeks on the medicine, patients and healthy controls will return to repeat the
questionnaires and the computer based decision-making tasks, and will again earn between
$5-40 based on their performance.
The overall goal of this study will be to identify whether decision-making characteristics in
people with major depression is affected by treatment, and whether depressed patients make
decisions differently from healthy controls. A total of 4 decision-making tasks and one
control task will be administered via computer to eligible subjects. The specific tasks are:
1. Risk Task - This task assesses tolerance of risk by having participants decide whether
they wish to accept a specific dollar payout, or to play a lottery with an uncertain
payout.
2. Balloon Analogue Risk Task - The participant is presented with a balloon and offered the
chance to earn money by pumping the balloon up by clicking a button. Each click causes
the balloon to incrementally inflate and money to be added to a counter up until some
threshold, at which point the balloon is over inflated and explodes. Thus, each pump
confers greater risk but also greater potential reward. If the participant chooses to
cash-out prior to the balloon exploding then they collect the money earned for that
trial, but if balloon explodes earnings for that trial are lost. Participants are not
informed about the balloons breakpoints; the absence of this information allows for
testing both participants' initial responses to the task and changes in responding as
they gain experience with the task contingencies.
3. Temporal Discounting Task - Participants are initially asked to choose between taking an
immediate reward now or a larger reward at some time in the future. Decisions for seven
time points over a 10-year time frame are proposed. The task is then repeated using
choices between immediate and delayed losses, based on the same seven time points. This
task assesses the manner in which subjects value immediate outcomes compared to
long-term consequences.
4. Ultimatum Game - The ultimatum game (UG) is a well-established game-theoretical paradigm
commonly employed in behavioral economics to measure emotional reactions to unfair
offers. In the UG, two subjects sequentially exchange real monetary amounts.
Specifically, a proposer is provided with a sum of money by the experimenter ($10), and
asked to share this amount of money with another player, the responder. The responder
then decides whether to accept or reject the offer made by the proposer. If the
responder accepts the offer, both players receive the respective amounts from the
proposer's offer. If she rejects the offer made by the proposer, both players receive
nothing ($0). This is best illustrated via the following two potential scenarios: 1. the
proposer offers a fair split of $5 for himself and $5 for the responder. This is an
offer that is typically accepted by a great majority of responders. 2. The proposer
offers a split of $9 for himself and $1 for the responder. Such offers are commonly
rejected by the majority of responders, despite incurring a financial loss of $1.
5. Continuous Performance Task - This task involves identifying patterns of numbers briefly
displayed on a computer screen. This task will serve as a control variable for attention
in analyzing the results of the decision-making tasks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |